Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for colorectal cancer, effective May 15, 2026, retiring the standalone policy and folding it into Section 220.6.17 of the National Coverage Determination framework. Here's what billing teams need to do.
This change consolidates how CMS governs FDG-PET imaging coverage for colorectal cancer billing. The old standalone policy is gone. Everything now lives under Section 220.6.17. If your practice bills for FDG-PET scans in a colorectal cancer context, you need to know where the rules now live — and confirm your documentation still aligns with them.
This policy does not list specific CPT or HCPCS codes in the available data. See the Affected Codes section below for guidance on how to handle that.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | FDG PET for Colorectal Cancer (Replaced with Section 220.6.17) — RETIRED |
| Policy Code | N/A |
| Change Type | Modified (Retirement / Consolidation) |
| Effective Date | 2026-05-15 |
| Impact Level | Medium |
| Specialties Affected | Oncology, Colorectal Surgery, Nuclear Medicine, Radiology, Gastroenterology |
| Key Action | Update internal policy references to Section 220.6.17 before May 15, 2026; confirm FDG-PET documentation requirements haven't shifted |
CMS FDG PET Colorectal Cancer Coverage Criteria and Medical Necessity Requirements 2026
The CMS FDG PET colorectal cancer coverage policy has been retired as a standalone document. Section 220.6.17 now governs coverage for FDG-PET imaging in this indication. That's not just an administrative footnote — it means any internal billing guidelines, payer checklists, or authorization workflows your team built around the old policy need to be updated to reference the new home.
FDG-PET stands for fluorodeoxyglucose positron emission tomography. CMS has long covered it for colorectal cancer under specific medical necessity criteria, generally tied to staging, restaging, and monitoring for recurrence. The retirement of the old policy doesn't eliminate coverage — it consolidates the rules under a broader NCD framework.
The real issue here is documentation continuity. When CMS moves a coverage policy into a new section, the criteria sometimes shift — even subtly. A prior authorization requirement that was phrased one way in the old document may be worded differently in Section 220.6.17. Your billing team and your medical director both need to read the new section against whatever documentation templates you're currently using.
Section 220.6.17 is part of the NCD Manual, which is administered nationally by the Centers for Medicare & Medicaid Services. Unlike a Local Coverage Determination (LCD), which varies by Medicare Administrative Contractor (MAC) region, this is a national rule. It applies uniformly. That's good news for multi-location practices that deal with different MACs — one standard, not five.
Whether FDG-PET is covered under Medicare for a given colorectal cancer patient depends on the clinical scenario. CMS has historically distinguished between covered indications — like staging and restaging — and non-covered ones, such as routine surveillance without a specific clinical question. Section 220.6.17 carries those distinctions forward. Confirm your coverage policy language matches the current section, not the retired one.
Prior authorization is not universally required for FDG-PET under Medicare, but that doesn't mean documentation requirements are light. Medical necessity must be established and documented before the scan. If your referring physicians aren't consistently documenting the clinical rationale — staging, recurrence evaluation, response assessment — you'll face claim denial under Section 220.6.17 just as you would have under the retired policy.
CMS FDG PET Exclusions and Non-Covered Indications
CMS has historically excluded certain FDG-PET uses from coverage in colorectal cancer. Routine surveillance scans — ordered without a specific clinical question about recurrence or treatment response — have generally not met medical necessity criteria. The consolidation into Section 220.6.17 doesn't change that pattern.
Screening use of FDG-PET in colorectal cancer is not a covered indication under Medicare. PET for initial diagnosis, absent staging intent, has also been a non-covered use. Your oncology billing team should flag any order that doesn't clearly tie to a staging, restaging, or recurrence evaluation purpose.
The practical risk: if your order entry or charge capture process doesn't prompt physicians to document the specific clinical question driving the PET scan, you'll generate claims that lack the medical necessity support required under the new Section 220.6.17 framework. Fix the workflow before May 15, 2026 — not after.
Coverage Indications at a Glance
The specific indication-level coverage criteria for Section 220.6.17 are not available in the policy data provided here. The table below reflects CMS's historically documented coverage positions for FDG-PET in colorectal cancer, based on the NCD framework. Confirm each row against the full text of Section 220.6.17 before the effective date of May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Staging of colorectal cancer | Covered (when medically necessary) | Not specified in policy data | Clinical documentation of staging intent required |
| Restaging after treatment | Covered (when medically necessary) | Not specified in policy data | Must document specific clinical question |
| Evaluation of suspected recurrence | Covered (when medically necessary) | Not specified in policy data | Rising CEA or clinical signs typically required |
| Monitoring treatment response | Covered (when medically necessary) | Not specified in policy data | Medical necessity documentation required |
| Routine surveillance without clinical indication | Not Covered | Not specified in policy data | Does not meet medical necessity criteria |
| Initial diagnosis / screening | Not Covered | Not specified in policy data | PET not a covered screening modality under Medicare |
Verify this table against Section 220.6.17 directly. CMS policy consolidations sometimes tighten or expand criteria, and you need the authoritative current text — not a summary — driving your billing decisions.
CMS FDG PET Colorectal Cancer Billing Guidelines and Action Items 2026
The effective date is May 15, 2026. That gives you a specific deadline to work backward from. Here's what to do now:
| # | Action Item |
|---|---|
| 1 | Pull your internal billing guidelines and cross-reference them against Section 220.6.17. Any reference to the retired standalone FDG PET colorectal cancer policy needs to be updated. This includes charge capture workflows, prior authorization checklists, and documentation templates. Do this before May 15, 2026. |
| 2 | Audit your FDG-PET order templates for colorectal cancer. Confirm that every order template prompts the ordering physician to document the specific clinical question — staging, restaging, suspected recurrence, or treatment response evaluation. Vague orders produce claims without adequate medical necessity support, and those produce claim denial. |
| 3 | Review your MAC's LCDs alongside Section 220.6.17. The NCD sets the national floor. Your Medicare Administrative Contractor may have published supplemental LCDs that interact with this NCD. Check for MAC-specific guidance that applies in your region, particularly if you operate across multiple states. |
| 4 | Brief your medical staff on the policy retirement. Physicians who order FDG-PET for colorectal cancer patients should know that the policy framework has changed. They don't need to read the NCD — but they do need to understand that documentation requirements remain in force under Section 220.6.17, and that the clinical rationale must be explicit in the chart. |
| 5 | Check your reimbursement audit trail for FDG-PET claims from the past 12 months. If you've had claim denial patterns on FDG-PET for colorectal cancer, use this policy transition as the trigger to investigate root cause. It's common for consolidation changes to surface documentation gaps that existed under the old policy framework. |
| 6 | Loop in your compliance officer if you're unsure how Section 220.6.17 changes your specific workflow. Policy consolidations look administrative on the surface but sometimes carry real criteria shifts. Don't assume the rules are identical until you've confirmed it. If your practice has high FDG-PET volume in colorectal cancer, this is worth a formal compliance review before the May 15 effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for FDG PET Colorectal Cancer Under CMS Section 220.6.17
The policy data provided for this change does not include specific CPT, HCPCS, or ICD-10 codes. CMS did not attach a code list to this policy modification in the available source data.
How to Find the Applicable Codes
FDG-PET billing in colorectal cancer typically involves PET scan procedure codes and associated radiopharmaceutical supply codes. To find the exact codes governed by Section 220.6.17, go directly to the NCD Manual and review Section 220.6.17 for any attached code tables or crosswalks.
You can also search your MAC's website for the LCD or billing article that corresponds to NCD 220.6.17 in your jurisdiction. MACs publish billing articles that list the covered CPT and HCPCS codes alongside the applicable ICD-10-CM diagnosis codes. Those articles are the operative billing reference for FDG-PET claims under Medicare.
Do not assume the code set is unchanged from the retired policy. Confirm it against the current Section 220.6.17 documentation before submitting claims after May 15, 2026.
Note on Code Tables
Because this policy data does not include specific codes, no code table is included here. Publishing invented codes would be worse than publishing none. Check the source policy directly and the current NCD Manual for the authoritative code list.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.